AllSight
Companies · NGNE · Pharmaceutical Preparations

Neurogene Inc. (NGNE)

Neurogene Inc. (NGNE) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Neurogene Inc. (NGNE) stock — financials & valuation

Key numbers for Neurogene Inc. (NGNE): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 36/100 — a percentile rank of Neurogene Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$556.7M
EV / EBITDA-3.8×
Return on equity-51.2%
ROIC-115.9%
Debt / equity0.0×
Dividend yield0.0%

Independent of the events above — derived from Neurogene Inc.’s own financial statements and shown as context, never as advice.

Aug 11, 2026
Long-term NGN-401 data strengthens the registration case; runway reaches 2029
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact